Lincomycin, clindamycin and their applications

Applied Microbiology and Biotechnology

Volumn 64, Issue 4, 2004, Pages 455-464

  Spizek J ^a   Rezanka T ^a  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN; ANTIBIOTIC AGENT; BENZOYL PEROXIDE; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLARITHROMYCIN; CLINDAMYCIN; CLINDAMYCIN PHOSPHATE; COTRIMOXAZOLE; ERYTHROMYCIN; IMMUNOGLOBULIN; LINCOMYCIN; LINCOSAMIDE DERIVATIVE; MIKAMYCIN B; PENICILLIN G; PRIMAQUINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RETINOIC ACID; RIBOSOME RNA; RIFAMYCIN DERIVATIVE; ROKITAMYCIN; ROXITHROMYCIN; STREPTOGRAMIN DERIVATIVE; TAZAROTENE; TETRACYCLINE DERIVATIVE; TYLOSIN; UNINDEXED DRUG; VIRGINIAMYCIN S;

MICROBIOLOGY;

ACNE; ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIOSTASIS; BACTERIUM; CHEMICAL MODIFICATION; CLINICAL PRACTICE; CONCENTRATION RESPONSE; DIARRHEA; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG UTILIZATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; IN VIVO STUDY; INHIBITION KINETICS; MALARIA; NONHUMAN; PROTEIN SYNTHESIS; PROTOZOAL INFECTION; PSEUDOMEMBRANOUS COLITIS; RNA METHYLATION; SHORT SURVEY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIPROTOZOAL AGENTS; BACTERIAL INFECTIONS; CLINDAMYCIN; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; LINCOMYCIN; PROTEIN BIOSYNTHESIS; PROTEIN SYNTHESIS INHIBITORS; PROTOZOA; PROTOZOAN INFECTIONS;

BACTERIA (MICROORGANISMS);

EID: 2542430327     PISSN: 01757598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00253-003-1545-7     Document Type: Short Survey

References (77)

1. Akhavan A, Bershad S (2003) Topical acne drugs review of clinical properties, systemic exposure, and safety. Am J Clin Dermatol 4:473-492
2. Amr S, Brown MB, Martin GP, Forbes B (2001) Activation of clindamycin phosphate by human skin. J Appl Microbiol 90:550-554
3. Bastian L, Weber S, Regel G (1997) Bacillus cereus pneumonia after severe thoracic trauma, case report and review of the literature. Anasthesiolog Intensivmed Notfallmed Schmerzther 32:124-129
4. Boselli E, Allaouchiche B (1999) Bone tissue diffusion of antibiotics. Presse Med 28:2265-2276
5. Bouvet A (1996) Severe infections due to Streptococcus pyogenes (group a streptococci). Med Malad Infect 6:803-808
6. Brook I (2002a) Clinical review: bacteremia caused by anaerobic bacteria in children. Crit Care 6:205-211
7. Brook I (2002b) The prophylaxis and treatment of anthrax. Int J Antimicrob Agents 20:320-325
8. Brook I, Frazier EH (1993) Significant recovery of nonsporulating anaerobic rods from clinical specimens. Clin Infect Dis 16:476-80
9. Bryskier A (2001) Anti-anaerobic activity of antibacterial agents. Expert Opinion Invest Drugs 10:239-267
10. Champney WS, Tober CL (2000) Specific inhibition of 50S ribosomal subunit formation in Staphylococcus aureus cells by 16-membered macrolide, lincosamide, and streptogramin B antibiotics. Curr Microbiol 41:126-135
11. Cooper AJ (1998) Systematic review of Propionibacterium acnes resistance to systemic antibiotics. Med J Aust 169:259-261
12. Coyle EA (2003) Targeting bacterial virulence: the role of protein synthesis inhibitors in severe infections - insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 23:638-642
13. Epstein ME, AmodioGroton M, Sadick NS (1997) Antimicrobial agents for the dermatologist. 2. Macrolides, fluoroquinolones, rifamycins, tetracyclines, trimethoprim-sulfamethoxazole, and clindamycin. J Am Acad Dermatol 37:365-381
14. Falagas ME, Siakavellas E (2000) Bacteroides, Prevotella, and Porphyromonas species: a review of antibiotic resistance and therapeutic options. Int J Antimicrob Agents 15:1-9
15. Fichera ME, Bhopale MK, Roos DS (1995) In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii. Antimicrob Agents Chemother 39:1530-1537
16. Fishman JA (1998) Treatment of infection due to Pneumocystis carinii. Antimicrob Agents Chemother 42:1309-1314
17. Freeman J, Wilcox MH (1999) Antibiotics and Clostridium difficile. Microbes Infect 1:377-384
18. Fung HB, Kirschenbaum HL (1996) Treatment regimens for patients with toxoplasmic encephalitis. Clin Ther 18:1037-1056
19. Green M, Wald ER (1996) Emerging resistance to antibiotics: impact on respiratory infections in the outpatient setting. Ann Allergy Asthma Immunol 77:167-173
20. Gross U, Pohl F (1996) Influence of antimicrobial agents on replication and stage conversion of Toxoplasma gondii. Curr Top Microbiol Immunol 219:235-245
21. Guay DRP (2003) Treatment of bacterial skin and skin structure infections. Expert Opinion Pharmacother 4:1259-1275
22. Harms JM, Bartels H, Schlunzen F, Yonath A (2003) Antibiotics acting on the translational machinery. J Cell Sci 116:1391-1393
23. Hopkins MJ, Macfarlane GT (2003) Nondigestible oligosaccharides enhance bacterial colonization resistance against Clostridium difficile in vitro. Appl Environ Microbiol 69:1920-1927
24. Jimenez-Diaz A, Reig M, Baquero F, Ballesta JP (1992) Antibiotic sensitivity of ribosomes from wild-type and clindamycin resistant Bacteroides vulgatus strains. J Antimicrob Chemother 30:295-301
25. Job ML, Jacobs NF (1997) Drug-induced Clostridium difficile-associated disease. Drug Saf 17:37-46
26. Kato MC, Hikosaka K, Hirose T (2002) Photoinactivation and recovery of photosystem II in Chenopodium album leaves grown at different levels of irradiance and nitrogen availability. Funct Plant Biol 29:787-795
27. Kimura T, Horii T, Morita M, Muramatsu H, Kanno T, Maekawa M (2003) Detection of macrolide resistance in Streptococcus pneumonie. Chemotherapy 49:56-61
28. Kjemtrup AM, Conrad PA (2000) Human babesiosis: an emerging tick-borne disease. Int J Parasitol 30:1323-1337
29. Klastersky J, Husson M (1977) Bactericidal activity of the combinations of gentamicin with clindamycin or chloramphenicol against species of Escherichia coli and Bacteroides fragilis. Antimicrob Agents Chemother 12:135-138
30. Kucers A, Hoy JF, Lindsay Grayson M, Crowe SM (1997) The use of antibiotics: a clinical review of antibacterial, antifungal and antiviral drugs, 5th edn. Oxford University Press, Oxford
31. Lell B, Kremsner PG (2002) Clindamycin as an antimalarial drug: review of clinical trials. Antimicrob Agents Chemother 46:2315-2320
32. Leng B, Meyers BR, Hirschman SZ, Keusch GT (1975) Susceptibilities of gram-negative bacteria to combinations of antimicrobial agents in vitro. Antimicrob Agents Chemother 8:164-171
33. Magerlein BJ (1971) Modification of lincomycin. Adv Appl Microbiol 14:185-229
34. Marcinak JF, Frank AL (2003) Treatment of community-acquired methicillin-resistant Staphylococcus aureus in children. Curr Opin Infect Dis 16:265-269
35. Matsuoka M (2000) Study of macrolide, lincosamide, and streptogramin B antibiotics resistance in Staphylococcus aureus. Yakugaku Zasshi 120:374-386
36. McGregor JA, French JI (2000) Bacterial vaginosis in pregnancy. Obstet Gynecol Surv [Suppl] 55: S1-S19
37. McManus MC (1997) Mechanisms of bacterial resistance to antimicrobial agents. Am J Health Syst Pharm 54:1420-1433
38. Melter O (2003) Detection and molecular characterization of methicillin resistant Staphylococcus aureus and Bartonella henselae in the Czech Republic. PhD thesis, Charles University, Prague
39. Mordmuller B, Graninger W, Kremsner PG (1998) Malaria chemotherapy in the time of chloroquine resistance. Wien Klin Wochenschr 110:321-325
40. Mylonakis E, Ryan ET, Calderwood SB (2001) Clostridium difficile-associated diarrhea - a review. Arch Intern Med 161:525-533
41. Noli C, Boothe D (1999) Macrolides and lincosamides. Vet Dermatol 10:217-223
42. Novotná G, Janata J, Kopecky J, Najmanova L, Spizek J (2002) Genes controlling MLS resistance in methicillin-resistant Staphylococcus aureus. In: Inter Academy Medical Panel (ed) Confronting infections, antibiotic resistance, and bioterrorism around the world. Elsevier, London, pp 169-170
43. Patenotte A, Dupuy O, Peyron F, Delolme H, Flechaire A (1995) Antibiotics and malaria - review of the literature. Med Malad Infect 25:970-975
44. Patey O, Varon E, Prazuck T, Podglajen I, Dublanchet A, Dubreuil L, Breuil J (1994) Multicentre survey in France of the antimicrobial susceptibilities of 416 blood culture isolates of the Bacteroides fragilis group. J Antimicrob Chemother 33:1029-1034
45. Piepersberg W, Distler J (1997) Aminoglycosides and sugar components in other secondary metabolites in biotechnology. In: Kleinkauf H, Dören H von (eds) Products of secondary metabolism. (Biotechnology, vol 7, 2nd edn) Wiley-VCH, Weinheim, pp 397-488
46. Priestley CJF, Kinghorn GR (1996) Bacterial vaginosis. Brit J Clin Pract 50:331-334
47. Reeves DS, Holt HA, Phillips I, King A, Miles RS, Paton R, Wise R, Andrews JM (1991) Activity of clindamycin against Staphylococcus aureus and Staphylococcus epidermidis from 4 UK centers. J Antimicrob Chemother 27:469-474
48. Reig M, Fernandez MC, Ballesta JP, Baquero F (1992a) Inducible expression of ribosomal clindamycin resistance in Bacteroides vulgatus. Antimicrob Agents Chemother 36:639-642
49. Reig M, Moreno A, Baquero F (1992b) Resistance of Peptostreptococcus spp to macrolides and lincosamides: inducible and constitutive phenotypes. Antimicrob Agents Chemother 36:662-664
50. Remington JS (1990) The role of clindamycin alone or in combination with another agent for the treatment of toxoplasmosis and pneumocystosis in AIDS. AM Medica Communications, New York
51. Rice RJ, Bhullar V, Mitchell SH, Bullard J, Knapp JS (1995) Susceptibilities of Chlamydia trachomatis isolates causing uncomplicated female genital-tract infections and pelvic inflammatory disease. Antimicrob Agents Chemother 39:760-762
52. Ridgway GL, Owen JM, Oriel JD (1978) The antimicrobial susceptibility of chlamyda trachomatis in cell culture. Br J Venereol Dis 54:103-105
53. Roos DS (1996) Molecular genetic tools for the identification and analysis of drug targets in Toxoplasma gondii. Curr Top Microbiol Immunol 219:247-259
54. Ross JI, Snelling AM, Carnegie E, Coates P, Cunliffe WJ, Bettoli V, Tosti G, Katsambas A, Del Pulgar JIGP, Rollman O, Torok L, Eady EA, Cove JH (2003) Antibiotic-resistant acne: lessons from Europe. Br J Dermatol 148:467-478
55. Sanders CC, Sanders WE Jr, Goering RV (1983) Effects of clindamycin on derepression of beta-lactamases in gramnegative bacteria. J Antimicrob Chemother 12 [Suppl C]:97-104
56. Schlievert PM, Kelly JA (1984) Clindamycin-induced suppression of toxic-shock syndrome associated exotoxin production. J Infect Dis 149:471
57. Schlunzen F, Zarivach R, Harms R, Bashan A, Tocilj A, Albrecht R, Yonath A, Franceschi F (2001) Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature 413:814-821
58. Seal DV (2001) Necrotizing fasciitis. Curr Opin Infect Dis 14:127-132
59. Sheridan RL, Ryan CM, Pasternack MS, Weber JM, Tompkins RG (1993) Flavobacterial sepsis in massively burned pediatric patients. Clin Infect Dis 17:185-187
60. Siberry GK, Tekle T, Carroll K, Dick J (2003) Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 37:1257-1260
61. Sicora C, Mate Z, Vass I (2003) The interaction of visible and UV-B light during photodamage and repair of photosystem II. Photosynth Res 75:127-137
62. Smieja M (1998) Current indications for the use of clindamycin: a critical review. J Can Infect Dis 9:22-28
63. Spizek J, Rezanka T (2004) Lincomycin, cultivation of producing strains and biosynthesis. Appl Microbiol Biotechnol (in press)
64. Stevens DL (1996) Invasive group A streptococcal disease. Infect Agents Dis Rev Issues Comment 5:157-166
65. Stevens DL (2000) Streptococcal toxic shock syndrome associated with necrotizing fasciitis. Annu Rev Med 51:271-288
66. Sztaricskai F, Dinya Z, Puskas MM, Batta G, Masuma R, Omura S (1996) Semisynthetic modification of antibiotic linkomycin. J Antibiot 49:941-943
67. Tanaka-Bandoh K, Kato N, Watanabe K, Ueno K (1995) Antibiotic susceptibility profiles of Bacteroides fragilis and Bacteroides thetaiotaomicron in Japan from 1990 to 1992. Clin Infect Dis 20 [Suppl 2]:S352-S355
68. Teng LJ, Hsueh PR, Tsai JC, Liaw SJ, Ho SW, Luh KT (2002) High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan. Antimicrob Agents Chemother 46:2908-2913
69. Thomas C, Stevenson M, Riley TV (2003) Antibiotics and hospitalacquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother 51:1339-1350
70. Turgeon P, Turgeon V, Gourdeau M, Dubois J, Lamothe F (1994) Longitudinal study of susceptibilities of species of the Bacteroides fragilis group to five antimicrobial agents in three medical centers. Antimicrob Agents Chemother 38:2276-2279
71. Uguen C, Girard L, Brasseur P, Leblay R (1997) Human babesiosis in 1997. Rev Med Interne 18:945-951
72. VanVlem B, Vanholder R, DePaepe P, Vogelaers D, Ringoir S (1996) Immunomodulating effects of antibiotics: literature review. Infection 24:275-291
73. Verdier L, Bertho G, Gharbi-Benarous J, Girault JP (2000) Lincomycin and clindamycin conformations. A fragment shared by macrolides, ketolides and lincosamides determined from TRNOE ribosome-bound conformations. Bioorg Med Chem 8:1225-1243
74. Veyssier-Belot C, Lejoyeux-Chartier F, Bouvet A (1999) Erysipela, cellulitis and other Streptococcus pyogenes skin infections. Presse Med 28:1959-1965
75. Wagner J, Jabbusch M, Eisenblatter M, Hahn H, Wendt C, Ignatius R (2003) Susceptibilities of Campylobacter jejuni isolates from Germany to ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and tetracycline. Antimicrob Agents Chemother 47:2358-2361
76. Walker C, Karpinia K (2002) Rationale for use of antibiotics in periodontics. J Periodontol 73:1188-1196
77. Warner GT, Plosker GL (2002) Clindamycin/benzoyl peroxide gel: a review of its use in the management of acne. Amer J Clin Dermatol 3:349-360